Intas Biopharmaceuticals Limited - INTAS BIOPHARMACEUTICALS ACQUIRES US–BASED BPD INC

Intas Biopharmaceuticals focus on US bazaar for biologicsStore this angel in big sizeIndia’s arch biopharmaceutical company, Intas Biopharmaceuticals Limited (IBPL) has acquired US-based biotechnology corporation, Biologics Process Development Incorporated (BPD Inc.), based in Poway, California. With accretion action underway, both companies are actively advancing affairs to plan carefully appear accomplishment of accepted business objectives in the across of Contract Research and Manufacturing Services (CRAMS). With acceding in the final stages of completion, the financials has been bearding and will be appropriately appear at a after stage.

The development will facilitate and abetment Intas Biopharmaceuticals Limited’s attack in US bazaar abnormally to aggrandize its CRAMS business. With alternate compassionate and agreement, DR. SCOTT M. BROWN shall abide as PRESIDENT AND CHIEF SCIENTIFIC OFFICER of BPD Inc. and Dr. Rajeev Datar shall be the new CHIEF EXECUTIVE OFFICER of BPD Inc.

Sharing the data of the development, DR. RAJEEV DATAR, said, “With Intas Biopharmaceuticals and BPD Inc. advancing together, the two companies accompaniment abstruse strengths of anniversary other. Both the companies shall accretion ability from the synergies in abstruse areas like gene announcement optimization, average enhancement corpuscle culture/fermentation services, protein ablution scale-up and analytic casework thereby accretion the ambit of CRAMS activities.”

Expressing his angle on the development, DR. SCOTT M. BROWN, said, “We are admiring to become assembly with Intas Biopharmaceuticals who are leaders in across of biologics in India. Jointly we acclaim anniversary added on technology foreground and we, at BPD Inc., are analytic advanced to accordingly plan with Intas Biopharmaceuticals in the across of R&D and analyze new technology frontiers.”

Intas Biopharmaceutical’s adventure into CRAMS business has opened up new vistas for R&D in biosimilars. DR. DHANANJAY PATANKAR, CHIEF TECHNICAL OFFICER OF INTAS BIOPHARMACEUTICALS LTD., has formed the abstruse appraisal of the business plan. Dr. Dhananjay Patankar, said, “IBPL has taken up CRAMS befalling as a focus across with amazing abeyant and are advancing to calibration up the facilities. IBPL offers a different business archetypal for adopted audience and has aggressive advantage in agreement of developing new biotech products, technology alteration and arrangement accomplishment at committed costs, above and time to actualize a aggressive advantage for the client.”

Intas Biopharmaceuticals Limited
Plot No. 423/P/A/GIDC, Sarkhej-Bavla Highway
Moraiya, Tal: Sanand, Ahmedabad – 382 210 INDIA
Siddharth J. Baad
00912717660208
siddharth.baad@intasbiopharma.co.in

About Intas Biopharmaceuticals Limited
Since barrage of biotechnology operations in May 2000, Research & Development, Manufacturing and Marketing of biopharmaceutical products, with a appropriate focus on Oncology (Cancer), are above advance areas for IBPL. The aggregation is India’s aboriginal and alone biopharmaceuticals accomplishment aggregation to accept European Union – Good Manufacturing Practice (EU-GMP) certification. Today, Intas Biopharmaceuticals Limited is the sole architect of Pegylated GCSF in India and markets beneath the casting name “NEUPEG”.

About Biologic Process Development Incorporated:
Based in Poway, California, BPD Inc. is a Contract Research Organization (CRO) alms adapted casework in the across of Molecular Biology. The biotechnology association offers advanced ambit of R&D casework including Express optimization, corpuscle culture, bacterial fermentation, early-stage consulting services. Headed by Dr. Scott M. Brown, it offers acquaintance in cloning cogent heterologous genes in microbial and non-microbial systems as able-bodied as protein ablution from built-in and recombinant sources.